It is clear that treatment with denosumab only partially addresses the therapeutic need of patients with a giant cell tumor by wiping out the osteoclasts but leaving the neoplastic stromal cells proliferative.
No takes yet. Share an insight, caveat, or question.
Mak et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: